The expansion is part of the company’s goal to expand its UK-based laboratory operations by 15% in 2017. According to the contract analytical chemistry provider, the securing the additional facility is the first step in a long-term plan to increase capacity by 60% by 2020.
“The key drivers for the expansion are growth of pharmaceutical output, particularly in the UK and Ireland and therefore continued demand for outsourced analytical support by leading global pharmaceutical companies,” the company told Outsourcing-Pharma.com in a statement.
According to Butterworth, the addition follows consistently strong growth, in addition to the recent appointment of David Hawkins, formerly the company's Chief Operating Officer, as Managing Director.
“We find ourselves in a changing market with the advent of Brexit and the growth of Biopharmaceuticals. It is now my task to provide a revised strategy and clear vision for the future to ensure our continuing success whilst maintaining the company’s culture along with its well deserved reputation for quality,” Hawkins told us.
“I am looking forward to the challenges the future brings and I have the greatest confidence that we have all the ingredients to continue with our success.”